Cognitive decline was slowed & amyloid brain plaques were cleared in people with Alzheimer's disease that were given targeted antibodies.
“The most robust effect from this trial was the breaking apart amyloid beta plaques in the brain, but the cognitive benefits were preliminary and depended on the type of test used to measure cognition.”